Go Pro
→ It Has Happened Before and the DOJ Just Confirmed It Is Happening Again (From Priority Gold) (Ad)tc pixel Free ATNM Stock Alerts

Actinium Pharmaceuticals (ATNM) Financials

Actinium Pharmaceuticals logo
$0.89 -0.03 (-3.24%)
Closing price 03:59 PM Eastern
Extended Trading
$0.89 0.00 (-0.45%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Actinium Pharmaceuticals

Annual Income Statements for Actinium Pharmaceuticals

This table shows Actinium Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -21 -24 -27 -24 -22 -22 -24 -33 -49 -38 -34
Consolidated Net Income / (Loss)		 -21 -24 -27 -24 -22 -22 -25 -33 -49 -38 -34
Net Income / (Loss) Continuing Operations		 -21 -24 -27 -24 -22 -22 -24 -33 -49 -38 -34
Total Pre-Tax Income 		-21 -24 -27 -24 -22 -22 -24 -33 -49 -38 -34
Total Operating Income		 -25 -27 -27 -24 -22 -22 -25 -34 -52 -42 -36
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 2.29 1.03 0.08 0.00 0.09
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 2.29 1.03 0.08 0.00 0.09
Operating Revenue		 0.00 0.00 0.00 0.00 - 0.00 2.29 1.03 0.08 0.00 0.09
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 25 27 27 24 22 22 26 35 52 42 36
Selling, General & Admin Expense		 11 9.02 9.19 6.73 5.52 6.31 8.08 12 13 12 15
Research & Development Expense		 14 18 18 17 17 16 18 23 39 30 21
Total Other Income / (Expense), net		 3.80 2.53 0.31 0.17 0.17 0.18 0.19 1.09 3.10 3.88 2.36
Interest & Investment Income		 -0.01 - - - - - - - 3.10 3.88 2.36
Basic Earnings per Share		 ($0.55) ($0.50) ($0.40) ($0.22) ($4.40) ($1.83) ($1.20) ($1.37) ($1.83) ($1.27) ($1.09)
Weighted Average Basic Shares Outstanding		 38.16M 48.46M 66.75M 106.04M 4.98M 12.13M 20.57M 24.14M 26.60M 30.07M 31.20M
Diluted Earnings per Share		 ($0.55) ($0.50) ($0.40) ($0.22) ($4.40) ($1.83) - - ($1.83) ($1.27) ($1.09)
Weighted Average Diluted Shares Outstanding		 38.16M 48.46M 66.75M 106.04M 4.98M 12.13M 20.57M 25.73M 26.60M 30.07M 31.20M
Weighted Average Basic & Diluted Shares Outstanding		 38.16M 48.46M 66.75M 106.04M 4.98M 12.13M 20.57M 25.73M 29.40M 31.20M 31.37M

Quarterly Income Statements for Actinium Pharmaceuticals

This table shows Actinium Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -13 -9.32 -8.67 -11 -12 -6.65 -16 -6.88 -5.13 -5.94 -5.52
Consolidated Net Income / (Loss)		 -13 -9.32 -8.67 -11 -12 -6.65 -16 -6.88 -5.13 -5.94 -5.52
Net Income / (Loss) Continuing Operations		 -13 -9.32 -8.67 -11 -12 -6.65 -16 -6.88 -5.13 -5.94 -5.52
Total Pre-Tax Income 		-13 -9.32 -8.67 -11 -12 -6.65 -16 -6.88 -5.13 -5.94 -5.52
Total Operating Income		 -14 -10 -9.60 -12 -13 -7.51 -17 -7.50 -5.69 -6.41 -5.90
Total Gross Profit		 0.00 0.08 0.00 0.00 0.00 - 0.00 0.00 0.09 - 0.00
Total Revenue		 0.00 0.08 0.00 0.00 0.00 - 0.00 0.00 0.09 - 0.00
Operating Revenue		 0.00 0.08 0.00 0.00 0.00 - 0.00 0.00 0.09 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 14 10 9.60 12 13 7.51 17 7.50 5.78 6.41 5.90
Selling, General & Admin Expense		 2.73 2.31 2.96 3.59 2.83 2.69 8.94 2.62 1.53 2.12 1.70
Research & Development Expense		 12 8.12 6.64 8.83 9.77 4.81 7.70 4.88 4.25 4.30 4.20
Total Other Income / (Expense), net		 1.08 1.02 0.93 1.07 1.03 0.85 0.70 0.63 0.56 0.47 0.38
Interest & Investment Income		 1.08 - 0.93 1.07 1.03 - 0.70 0.63 0.56 0.47 0.38
Basic Earnings per Share		 ($0.49) ($0.33) ($0.31) ($0.38) ($0.37) ($0.21) ($0.51) ($0.22) ($0.16) ($0.20) ($0.18)
Weighted Average Basic Shares Outstanding		 27.06M 26.60M 27.89M 30.10M 31.07M 30.07M 31.20M 31.20M 31.20M 31.20M 31.24M
Diluted Earnings per Share		 ($0.49) - ($0.31) ($0.38) ($0.37) - ($0.51) ($0.22) ($0.16) ($0.20) ($0.18)
Weighted Average Diluted Shares Outstanding		 27.06M 26.60M 27.89M 30.10M 31.07M 30.07M 31.20M 31.20M 31.20M 31.20M 31.24M
Weighted Average Basic & Diluted Shares Outstanding		 27.41M 29.40M 29.78M 31.15M 31.20M 0.00 31.20M 31.20M 31.20M 0.00 31.37M

Annual Cash Flow Statements for Actinium Pharmaceuticals

This table details how cash moves in and out of Actinium Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 19 -5.12 -2.76 -3.69 -4.41 54 14 31 -33 -3.76 -25
Net Cash From Operating Activities		 -19 -21 -22 -21 -21 -22 -21 8.64 -47 -33 -25
Net Cash From Continuing Operating Activities		 -19 -21 -22 -21 -21 -22 -21 8.64 -47 -33 -25
Net Income / (Loss) Continuing Operations		 -21 -24 -27 -24 -22 -22 -25 -33 -49 -38 -34
Consolidated Net Income / (Loss)		 -21 -24 -27 -24 -22 -22 -25 -33 -49 -38 -34
Depreciation Expense		 0.05 0.08 0.06 0.05 0.42 0.45 0.52 0.70 0.21 0.20 0.17
Amortization Expense		 - - - - - - - - 0.58 0.61 0.65
Non-Cash Adjustments To Reconcile Net Income		 3.25 1.77 3.19 1.80 1.30 0.94 1.69 2.80 3.32 5.29 9.19
Changes in Operating Assets and Liabilities, net		 -0.82 1.69 1.80 1.23 -1.23 -0.79 1.69 38 -2.62 -0.93 -0.70
Net Cash From Investing Activities		 -0.05 -0.11 -0.02 -0.10 -0.06 -0.25 -0.13 -0.37 -0.15 -0.01 -0.10
Net Cash From Continuing Investing Activities		 -0.05 -0.11 -0.02 -0.10 -0.06 -0.25 -0.13 -0.37 -0.15 -0.01 -0.10
Purchase of Property, Plant & Equipment		 -0.05 -0.06 -0.02 -0.10 -0.06 -0.25 -0.13 -0.37 -0.15 -0.01 -0.10
Net Cash From Financing Activities		 38 16 19 17 17 76 35 23 15 29 -0.22
Net Cash From Continuing Financing Activities		 38 16 19 17 17 76 35 23 15 29 -0.22
Repayment of Debt		 -0.28 -0.27 0.00 0.00 -0.25 -0.38 - -0.05 -0.00 -0.01 -0.01
Issuance of Common Equity		 38 16 19 17 17 77 - 23 15 29 0.00
Other Financing Activities, net		 0.17 0.02 0.00 0.00 -0.07 -0.03 35 0.00 0.26 0.08 -0.21
Other Net Changes in Cash		 - - - - - - - - - 0.00 0.01

Quarterly Cash Flow Statements for Actinium Pharmaceuticals

This table details how cash moves in and out of Actinium Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -8.30 -6.30 7.38 1.98 -7.37 -5.75 -7.58 -5.40 -6.53 -5.39 -5.86
Net Cash From Operating Activities		 -11 -7.49 -7.37 -7.97 -12 -5.75 -7.57 -5.39 -6.33 -5.29 -5.87
Net Cash From Continuing Operating Activities		 -11 -7.49 -7.37 -7.97 -12 -5.75 -7.57 -5.39 -6.33 -5.29 -5.87
Net Income / (Loss) Continuing Operations		 -13 -9.32 -8.67 -11 -12 -6.65 -16 -6.88 -5.13 -5.94 -5.52
Consolidated Net Income / (Loss)		 -13 -9.32 -8.67 -11 -12 -6.65 -16 -6.88 -5.13 -5.94 -5.52
Depreciation Expense		 0.20 -0.38 0.22 0.19 0.20 -0.41 0.05 0.20 0.21 -0.44 0.03
Amortization Expense		 - - - - - - 0.16 - - - 0.19
Non-Cash Adjustments To Reconcile Net Income		 0.92 0.93 1.38 1.37 1.34 1.20 8.87 0.20 0.11 0.01 0.01
Changes in Operating Assets and Liabilities, net		 1.03 0.71 -0.30 1.82 -1.95 -0.51 -0.72 1.09 -1.51 0.44 -0.58
Net Cash From Investing Activities		 -0.03 - -0.01 - - - 0.00 - - -0.10 -0.00
Net Cash From Continuing Investing Activities		 -0.03 - -0.01 - - - 0.00 - - -0.10 -0.00
Purchase of Property, Plant & Equipment		 -0.03 - -0.01 - - - 0.00 - - -0.10 -0.00
Net Cash From Financing Activities		 2.86 1.19 15 9.95 4.60 -0.00 -0.00 -0.00 -0.21 -0.00 -0.00
Net Cash From Continuing Financing Activities		 2.86 1.19 15 9.95 4.60 -0.00 -0.00 -0.00 -0.21 -0.00 -0.00
Repayment of Debt		 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00
Other Net Changes in Cash		 - - - - - - 0.00 - - - 0.01

Annual Balance Sheets for Actinium Pharmaceuticals

This table presents Actinium Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 27 23 18 15 12 66 80 114 81 77 52
Total Current Assets		 26 22 18 14 10 65 80 111 78 75 49
Cash & Equivalents		 26 21 17 14 9.25 64 78 109 77 73 48
Prepaid Expenses		 0.80 1.84 0.44 0.62 0.79 1.32 1.48 1.64 1.59 1.60 1.38
Plant, Property, & Equipment, net		 0.11 0.09 0.06 0.12 0.11 0.31 0.34 0.60 0.55 0.36 0.30
Total Noncurrent Assets		 0.00 0.05 0.44 0.44 1.47 1.16 -0.00 2.65 2.63 2.03 2.10
Noncurrent Note & Lease Receivables		 - - - 0.00 0.22 0.14 -0.00 0.00 0.03 0.02 0.01
Other Noncurrent Operating Assets		 0.00 0.05 0.44 0.44 1.25 1.02 - 2.64 2.60 2.01 2.09
Total Liabilities & Shareholders' Equity		 27 23 18 15 12 66 80 114 81 77 52
Total Liabilities		 4.61 4.52 4.67 6.08 6.03 5.08 6.84 48 45 44 44
Total Current Liabilities		 4.61 4.52 4.67 6.06 5.34 4.77 6.84 11 8.49 8.15 7.97
Accounts Payable		 1.50 4.22 4.65 5.81 4.60 - 5.54 - 7.95 7.57 7.25
Other Current Liabilities		 2.85 0.30 0.02 0.00 0.37 0.43 1.31 0.50 0.54 0.58 0.72
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.01 0.68 0.31 0.00 37 37 36 36
Noncurrent Deferred Revenue		 - - - - - - - 35 35 35 35
Other Noncurrent Operating Liabilities		 - - - 0.01 0.68 0.31 - 2.08 1.55 0.98 0.97
Commitments & Contingencies		 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 22 18 14 8.81 5.64 61 74 66 36 33 7.83
Total Preferred & Common Equity		 22 18 14 8.81 5.64 61 74 66 36 33 7.83
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 22 18 14 8.81 5.64 61 74 66 36 33 7.83
Common Stock		 134 155 177 196 214 292 329 355 374 409 418
Retained Earnings		 -112 -137 -163 -187 -209 -231 -256 -289 -338 -376 -410
Accumulated Other Comprehensive Income / (Loss)		 - - - - - - - - - 0.00 -0.02

Quarterly Balance Sheets for Actinium Pharmaceuticals

This table presents Actinium Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 89 88 90 82 69 63 56 45
Total Current Assets		 86 85 87 80 66 61 54 43
Cash & Equivalents		 83 84 86 79 65 60 53 42
Prepaid Expenses		 2.62 1.32 1.03 0.86 1.13 1.10 0.98 1.13
Plant, Property, & Equipment, net		 0.60 0.50 0.46 0.41 0.32 0.27 0.23 0.27
Total Noncurrent Assets		 2.75 2.48 2.33 2.18 1.87 1.72 1.56 1.91
Noncurrent Note & Lease Receivables		 0.00 0.03 0.03 0.02 0.02 0.02 0.01 0.01
Other Noncurrent Operating Assets		 2.75 2.46 2.31 2.16 1.86 1.70 1.55 1.90
Total Liabilities & Shareholders' Equity		 89 88 90 82 69 63 56 45
Total Liabilities		 45 44 46 44 43 44 42 43
Total Current Liabilities		 8.67 8.06 9.73 7.76 7.11 8.31 6.83 7.35
Accounts Payable		 - - 9.18 7.20 6.52 7.71 6.22 6.62
Other Current Liabilities		 0.52 0.55 0.55 0.56 0.59 0.60 0.61 0.73
Total Noncurrent Liabilities		 37 36 36 36 36 36 36 36
Noncurrent Deferred Revenue		 35 35 35 35 35 35 35 35
Other Noncurrent Operating Liabilities		 1.69 1.41 1.28 1.14 0.84 0.69 0.53 0.79
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 44 44 44 38 26 19 14 2.30
Total Preferred & Common Equity		 44 44 44 38 26 19 14 2.30
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 44 44 44 38 26 19 14 2.30
Common Stock		 372 390 401 407 417 418 418 418
Retained Earnings		 -328 -346 -358 -369 -392 -399 -404 -415
Accumulated Other Comprehensive Income / (Loss)		 - - - - - - - -0.04

Annual Metrics And Ratios for Actinium Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Actinium Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 42,017,499.00 55,747,108.00 80,025,639.00 115,698,044.00 164,701,167.00 13,586,525.00 22,030,838.00 25,483,306.00 27,413,441.00 - 27,413,441.00
DEI Adjusted Shares Outstanding		 1,400,583.00 1,858,237.00 2,667,521.00 3,856,601.00 5,490,039.00 13,586,525.00 22,030,838.00 25,483,306.00 27,413,441.00 - 27,413,441.00
DEI Earnings Per Adjusted Shares Outstanding		 -15.01 -13.09 -9.97 -6.13 -3.99 -1.64 -1.07 -1.30 -1.78 - -1.24
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -54.98% -92.14% -100.00% 0.00%
EBITDA Growth		 14.95% -15.62% -9.54% 10.45% 9.66% -2.17% -11.36% -36.68% -53.06% 19.21% 14.24%
EBIT Growth		 14.86% -15.70% -9.42% 10.45% 8.09% -2.25% -11.48% -36.61% -52.24% 18.87% 13.95%
NOPAT Growth		 -10.45% -8.13% -0.24% 11.46% 7.37% -1.45% -11.48% -36.61% -52.24% 18.87% 13.95%
Net Income Growth		 14.83% -15.68% -9.37% 11.08% 7.42% -1.44% -11.52% -33.27% -47.86% 21.66% 11.39%
EPS Growth		 38.89% 9.09% 20.00% 45.00% 7.42% 58.41% 0.00% 0.00% 0.00% 30.60% 14.17%
Operating Cash Flow Growth		 -29.24% -12.11% -3.68% 4.56% -4.33% -0.72% 3.47% 141.43% -647.61% 30.13% 25.68%
Free Cash Flow Firm Growth		 -56.20% 11.81% 10.32% 10.75% -6.78% -24.83% 50.25% 136.82% -847.56% -3.01% 14.45%
Invested Capital Growth		 58.97% 25.96% -46.46% -24.75% 29.55% 162.59% -342.56% -557.19% -23.20% 0.35% -0.07%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 104.10% -67.63% 108.22% -100.00% 0.00%
EBITDA Q/Q Growth		 -5.64% -0.60% 5.40% -5.10% 8.49% -8.85% -6.99% -10.66% 1.89% 6.44% 4.60%
EBIT Q/Q Growth		 -5.60% -0.64% 5.43% -5.10% 7.99% -8.74% -6.91% -10.51% 1.79% 6.31% 2.92%
NOPAT Q/Q Growth		 7.29% -7.65% 5.68% -5.10% 7.26% -8.74% -6.91% -10.51% 1.79% 6.31% 2.92%
Net Income Q/Q Growth		 -5.60% -0.64% 5.45% -5.14% 7.27% -8.69% -7.04% -8.68% 2.64% 6.53% 2.06%
EPS Q/Q Growth		 -5.77% 7.41% -2.56% -10.00% 7.27% -38.64% 0.00% 0.00% 0.00% 0.00% 0.91%
Operating Cash Flow Q/Q Growth		 5.52% -1.35% 4.74% -5.75% -3.49% -6.12% 5.46% -23.98% 0.60% 5.00% 1.84%
Free Cash Flow Firm Q/Q Growth		 14.88% -9.17% 4.87% -2.68% -8.37% -31.29% 39.84% 116.44% -399.08% -33.00% 6.03%
Invested Capital Q/Q Growth		 -80.74% -91.68% -36.04% -42.44% 25.52% 172.81% -177.16% 0.00% -28.91% 0.75% -1.41%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 0.00% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,068.18% -3,243.20% -63,123.46% 0.00% -39,362.22%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,091.08% -3,311.07% -64,098.77% 0.00% -40,274.44%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,091.08% -3,311.07% -64,098.77% 0.00% -40,274.44%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,082.78% -3,205.53% -60,269.14% 0.00% -37,652.22%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 104.84% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.04% 100.02% 99.98% 99.27% 100.00% 99.21% 94.66% 96.81% 94.03% 90.79% 93.49%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -209.71% -121.66% -167.94% -210.41% -302.97% -66.35% -36.74% -47.16% -94.92% -110.63% -166.96%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -1,024.04% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -34.01% -35.05% -53.08% 0.00% -56.34%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -33.76% -33.94% -49.91% 0.00% -52.67%
Return on Common Equity (ROCE)		 -209.71% -121.66% -167.94% -210.41% -302.97% -66.35% -36.74% -47.16% -94.92% -110.63% -166.96%
Return on Equity Simple (ROE_SIMPLE)		 -95.68% -135.06% -194.58% -268.40% -388.02% -36.23% -33.69% -49.66% -134.19% -116.74% 0.00%
Net Operating Profit after Tax (NOPAT)		 -17 -19 -19 -17 -15 -16 -17 -24 -36 -29 -25
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -763.76% -2,317.75% -44,869.14% 0.00% -28,192.11%
Net Nonoperating Expense Percent (NNEP)		 -22.87% -24.05% -40.91% -45.20% -57.62% -19.18% -10.59% -10.29% -14.19% -11.71% -14.09%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -99.85% -89.98% -323.88%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 353.02% 1,164.95% 16,458.02% 0.00% 16,903.33%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 788.07% 2,246.12% 47,740.74% 0.00% 23,471.11%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,141.08% 3,411.07% 64,198.77% 0.00% 40,374.44%
Earnings before Interest and Taxes (EBIT)		 -21 -24 -27 -24 -22 -22 -25 -34 -52 -42 -36
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -21 -24 -27 -24 -21 -22 -24 -33 -51 -41 -35
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 5.61 2.35 3.24 4.66 5.76 1.54 1.68 4.12 3.72 1.16 5.42
Price to Tangible Book Value (P/TBV)		 5.61 2.35 3.24 4.66 5.76 1.54 1.68 4.12 3.72 1.16 5.42
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 54.03 266.04 1,668.50 0.00 471.40
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 17.25 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 19.84 169.75 722.11 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 20.23 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 45.45 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.01 0.00 0.00 0.03 0.07 0.07 0.00 0.15 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.59 -1.15 -1.20 -1.37 -1.55 -1.02 -1.02 -1.27 -1.71 -2.16 -2.98
Leverage Ratio		 1.70 1.23 1.29 1.48 1.84 1.17 1.09 1.39 1.90 2.29 3.17
Compound Leverage Factor		 1.70 1.23 1.29 1.47 1.84 1.16 1.03 1.35 1.79 2.08 2.96
Debt to Total Capital		 1.19% 0.00% 0.00% 2.75% 6.32% 6.61% 0.00% 13.22% 0.05% 0.03% 0.00%
Short-Term Debt to Total Capital		 1.19% 0.00% 0.00% 2.75% 6.32% 6.61% 0.00% 13.22% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.05% 0.03% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 98.81% 100.00% 100.00% 97.25% 93.68% 93.39% 100.00% 86.78% 99.95% 99.97% 100.00%
Debt to EBITDA		 -0.01 0.00 0.00 -0.01 -0.02 -0.20 0.00 -0.30 0.00 0.00 0.00
Net Debt to EBITDA		 1.21 0.00 0.00 0.57 0.42 2.70 0.00 2.97 1.50 1.76 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.02 0.00 0.00 -0.01 -0.02 -0.28 0.00 -0.42 0.00 0.00 0.00
Net Debt to NOPAT		 1.46 0.00 0.00 0.81 0.58 3.78 0.00 4.15 2.11 2.47 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 8.50 -5.47 -10.69 -18.13 -27.51 6.29 6.48 -0.02 -5.08 -7.10 -11.85
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.74 4.95 3.82 2.36 1.89 13.62 11.66 10.44 9.21 9.14 6.20
Quick Ratio		 5.56 4.54 3.73 2.26 1.73 13.33 11.38 10.25 9.03 8.95 6.02
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -22 -20 -18 -16 -17 -21 -10 3.85 -29 -30 -25
Operating Cash Flow to CapEx		 -38,804.24% -34,671.84% -87,122.95% -21,407.67% -33,534.38% -8,544.27% -15,688.72% 2,361.75% -30,937.91% -300,654.55% -23,634.62%
Free Cash Flow to Firm to Interest Expense		 0.00 -3,931.66 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 -4,152.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -4,164.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.01 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 7.02 2.18 0.14 0.00 0.27
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -3.44 -2.55 -3.73 -4.65 -3.28 2.05 -4.98 -33 -40 -40 -40
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 -1.57 -0.05 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 4.94 0.89 -1.18 -0.92 1.37 5.33 -7.03 -28 -7.58 0.14 -0.03
Enterprise Value (EV)		 98 22 27 28 24 35 45 175 58 -35 -5.57
Market Capitalization		 123 42 44 41 32 95 124 274 135 38 42
Book Value per Share		 $0.52 $0.32 $0.17 $0.08 $0.03 $4.51 $3.34 $2.64 $1.33 $1.09 $0.25
Tangible Book Value per Share		 $0.52 $0.32 $0.17 $0.08 $0.03 $4.51 $3.34 $2.64 $1.33 $1.09 $0.25
Total Capital		 22 18 14 9.06 6.03 66 74 77 36 33 7.83
Total Debt		 0.27 0.00 0.00 0.25 0.38 4.34 0.00 10 0.02 0.01 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.01 0.00
Net Debt		 -25 -21 -17 -13 -8.92 -59 -78 -99 -77 -73 -48
Capital Expenditures (CapEx)		 0.05 0.06 0.02 0.10 0.06 0.25 0.13 0.37 0.15 0.01 0.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.54 -2.68 -4.23 -5.20 -4.18 0.89 -5.31 1.14 -6.91 -6.55 -6.59
Debt-free Net Working Capital (DFNWC)		 22 18 13 8.52 5.13 64 73 110 70 66 41
Net Working Capital (NWC)		 22 18 13 8.27 4.74 60 73 100 70 66 41
Net Nonoperating Expense (NNE)		 3.64 5.53 7.76 6.97 6.45 6.54 7.30 9.14 12 8.76 8.51
Net Nonoperating Obligations (NNO)		 -25 -21 -17 -13 -8.92 -59 -79 -99 -77 -73 -48
Total Depreciation and Amortization (D&A)		 0.05 0.08 0.06 0.05 0.42 0.45 0.52 0.70 0.79 0.81 0.82
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -232.17% 110.49% -8,528.40% 0.00% -7,317.78%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3,186.58% 10,722.72% 86,134.57% 0.00% 46,013.33%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3,186.58% 9,739.22% 86,134.57% 0.00% 46,013.33%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($16.50) ($15.00) ($12.00) ($6.60) ($4.50) ($1.83) ($1.20) ($1.37) ($1.83) ($1.27) ($1.09)
Adjusted Weighted Average Basic Shares Outstanding		 1.48M 1.86M 3.67M 3.97M 165.86K 19.25M 22.14M 24.14M 26.60M 30.07M 31.20M
Adjusted Diluted Earnings per Share		 ($16.50) ($15.00) ($12.00) ($6.60) ($4.50) ($1.83) ($1.20) $0.00 $0.00 ($1.27) ($1.09)
Adjusted Weighted Average Diluted Shares Outstanding		 1.48M 1.86M 3.67M 3.97M 165.86K 19.25M 22.14M 25.73M 29.40M 30.07M 31.20M
Adjusted Basic & Diluted Earnings per Share		 ($16.50) ($15.00) ($12.00) ($6.60) ($4.50) ($1.83) ($1.20) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.27M 1.62M 2.22M 3.53M 4.98M 12.13M 20.57M 25.73M 29.40M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -17 -19 -19 -17 -15 -16 -17 -24 -36 -29 -25
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -763.76% -2,317.75% -44,869.14% 0.00% -28,192.11%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,032.78% -3,205.53% -60,269.14% 0.00% -37,652.22%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 -4,856.54 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 -3,753.39 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 -4,868.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 -3,765.37 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Actinium Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Actinium Pharmaceuticals' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 26,997,587.00 27,413,441.00 27,413,441.00 27,413,441.00 27,413,441.00 - 27,413,441.00 27,413,441.00 27,413,441.00 27,413,441.00 27,413,441.00
DEI Adjusted Shares Outstanding		 26,997,587.00 27,413,441.00 27,413,441.00 27,413,441.00 27,413,441.00 - 27,413,441.00 27,413,441.00 27,413,441.00 27,413,441.00 27,413,441.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.49 -0.34 -0.32 -0.41 -0.42 - -0.58 -0.25 -0.19 -0.22 -0.20
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -100.00% 108.22% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -47.74% 3.62% 17.73% 20.76% 12.38% 26.21% -75.17% 40.31% 55.75% 13.38% 65.42%
EBIT Growth		 -46.45% 8.40% 17.15% 20.61% 12.19% 27.44% -73.37% 39.58% 54.83% 14.54% 64.52%
NOPAT Growth		 -46.45% 8.40% 17.15% 20.61% 12.19% 27.44% -73.37% 39.58% 54.83% 14.54% 64.52%
Net Income Growth		 -40.13% 12.43% 21.45% 25.22% 12.87% 28.66% -83.83% 39.42% 55.64% 10.70% 65.35%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 24.49% 0.00% -64.52% 42.11% 56.76% 4.76% 64.71%
Operating Cash Flow Growth		 -94.66% 3.70% 51.09% 41.57% -7.64% 23.22% -2.71% 32.36% 47.18% 8.03% 22.50%
Free Cash Flow Firm Growth		 344.96% -98.26% -145.18% 14.86% -98.23% -1,668.92% 60.10% -38.83% -1,387.58% 17.29% 16.29%
Invested Capital Growth		 0.00% -23.20% 13.37% -10.44% -29.43% 0.35% -21.29% 3.03% 2.06% -0.07% -0.51%
Revenue Q/Q Growth		 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 8.31% 24.20% 12.55% -30.36% -1.39% 36.16% -107.62% 55.58% 24.84% -24.97% 17.11%
EBIT Q/Q Growth		 8.25% 27.93% 7.21% -29.39% -1.47% 40.44% -121.69% 54.90% 24.14% -12.68% 7.97%
NOPAT Q/Q Growth		 8.25% 27.93% 7.21% -29.39% -1.47% 40.44% -121.69% 54.90% 24.14% -12.68% 7.97%
Net Income Q/Q Growth		 12.55% 29.77% 7.01% -30.95% -1.89% 42.50% -139.60% 56.85% 25.40% -15.77% 7.04%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -22.58% 2.63% 0.00% -142.86% 56.86% 27.27% -25.00% 10.00%
Operating Cash Flow Q/Q Growth		 18.46% 32.67% 1.55% -8.11% -50.21% 51.97% -31.70% 28.81% -17.30% 16.38% -10.99%
Free Cash Flow Firm Q/Q Growth		 483.74% -98.38% -3,519.86% 60.01% 107.96% -1,541.49% 13.03% -39.16% 26.20% 7.40% 11.98%
Invested Capital Q/Q Growth		 18.20% -28.91% 18.89% -29.13% 4.14% 0.75% 1.28% -3.25% 3.19% -1.41% 0.84%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 0.00% 0.00%
EBITDA Margin		 0.00% -13,243.21% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -6,095.56% 0.00% 0.00%
Operating Margin		 0.00% -12,769.14% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -6,324.44% 0.00% 0.00%
EBIT Margin		 0.00% -12,769.14% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -6,324.44% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% -11,511.11% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -5,701.11% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 92.51% 90.15% 90.34% 91.42% 91.80% 88.63% 95.79% 91.67% 90.14% 92.61% 93.55%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -115.05% -94.92% -91.92% -87.96% -100.05% -110.63% -130.87% -130.59% -133.09% -166.96% -167.66%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -10.57% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8.23% 0.00% 0.00%
Return on Assets (ROA)		 0.00% -9.53% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7.42% 0.00% 0.00%
Return on Common Equity (ROCE)		 -115.05% -94.92% -91.92% -87.96% -100.05% -110.63% -130.87% -130.59% -133.09% -166.96% -167.66%
Return on Equity Simple (ROE_SIMPLE)		 -115.05% 0.00% -105.91% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -10 -7.24 -6.72 -8.69 -8.82 -5.25 -12 -5.25 -3.98 -4.49 -4.13
NOPAT Margin		 0.00% -8,938.40% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4,427.11% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -8.63% -2.37% -2.28% -3.00% -3.58% -1.87% -6.05% -2.23% -1.74% -2.40% -2.59%
Return On Investment Capital (ROIC_SIMPLE)		 - -19.89% -13.07% -19.82% -23.08% -16.03% -45.32% -27.62% -28.90% -57.31% -179.34%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 2,846.91% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,704.44% 0.00% 0.00%
R&D to Revenue		 0.00% 10,022.22% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4,720.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 12,869.14% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6,424.44% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -14 -10 -9.60 -12 -13 -7.51 -17 -7.50 -5.69 -6.41 -5.90
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -14 -11 -9.38 -12 -12 -7.92 -16 -7.30 -5.49 -6.86 -5.68
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.68 3.72 4.98 5.08 1.53 1.16 1.95 2.30 3.62 5.42 13.49
Price to Tangible Book Value (P/TBV)		 3.68 3.72 4.98 5.08 1.53 1.16 1.95 2.30 3.62 5.42 13.49
Price to Revenue (P/Rev)		 0.00 1,668.50 2,695.69 2,750.16 721.16 0.00 0.00 0.00 554.59 471.40 345.45
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 722.11 1,750.92 1,688.14 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.19 0.00 0.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.72 -1.71 -1.70 -1.83 -1.88 -2.16 -2.04 -2.32 -2.54 -2.98 -3.84
Leverage Ratio		 2.04 1.90 1.88 1.95 2.09 2.29 2.26 2.43 2.66 3.17 4.07
Compound Leverage Factor		 1.89 1.71 1.70 1.78 1.92 2.03 2.16 2.23 2.40 2.94 3.81
Debt to Total Capital		 15.75% 0.05% 14.65% 0.03% 0.03% 0.03% 0.03% 0.03% 0.01% 0.00% 0.00%
Short-Term Debt to Total Capital		 15.75% 0.00% 14.62% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.05% 0.03% 0.03% 0.03% 0.03% 0.03% 0.03% 0.01% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 84.25% 99.95% 85.35% 99.97% 99.97% 99.97% 99.97% 99.97% 99.99% 100.00% 100.00%
Debt to EBITDA		 -0.16 0.00 -0.15 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 1.44 1.50 1.54 1.85 1.76 1.76 1.33 1.36 1.44 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.22 0.00 -0.22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 2.02 2.11 2.19 2.63 2.50 2.47 1.90 1.93 2.04 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -2.55 -3.39 -1.85 -2.09 -4.95 -5.61 -7.05 -7.65 -8.68 -9.95 -11.84
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 9.87 9.21 10.59 8.95 10.25 9.14 9.35 7.34 7.96 6.20 5.89
Quick Ratio		 9.57 9.03 10.42 8.84 10.14 8.95 9.19 7.21 7.81 6.02 5.73
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 21 0.34 -12 -4.70 0.37 -5.40 -4.69 -6.53 -4.82 -4.46 -3.93
Operating Cash Flow to CapEx		 -37,083.33% 0.00% -67,036.36% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -5,085.58% -293,500.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.14 0.14 0.15 0.16 0.00 0.00 0.00 0.28 0.27 0.31
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -31 -40 -33 -42 -40 -40 -40 -41 -40 -40 -40
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -31 -7.58 5.04 -3.99 -9.20 0.14 -6.95 1.28 0.84 -0.03 -0.20
Enterprise Value (EV)		 85 58 142 137 -20 -35 -15 -16 -3.48 -5.57 -11
Market Capitalization		 160 135 218 223 58 38 50 44 50 42 31
Book Value per Share		 $1.61 $1.33 $1.57 $1.46 $1.23 $1.09 $0.82 $0.61 $0.44 $0.25 $0.07
Tangible Book Value per Share		 $1.61 $1.33 $1.57 $1.46 $1.23 $1.09 $0.82 $0.61 $0.44 $0.25 $0.07
Total Capital		 52 36 51 44 38 33 26 19 14 7.83 2.30
Total Debt		 8.15 0.02 7.53 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00
Net Debt		 -75 -77 -77 -86 -79 -73 -65 -60 -53 -48 -42
Capital Expenditures (CapEx)		 0.03 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.10 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 2.10 -6.91 0.77 -8.70 -6.90 -6.55 -5.98 -7.21 -5.86 -6.59 -6.22
Debt-free Net Working Capital (DFNWC)		 85 70 85 77 72 66 59 53 48 41 36
Net Working Capital (NWC)		 77 70 77 77 72 66 59 53 48 41 36
Net Nonoperating Expense (NNE)		 3.23 2.08 1.95 2.66 2.75 1.40 4.29 1.63 1.15 1.45 1.39
Net Nonoperating Obligations (NNO)		 -75 -77 -77 -86 -79 -73 -65 -60 -53 -48 -42
Total Depreciation and Amortization (D&A)		 0.20 -0.38 0.22 0.19 0.20 -0.41 0.21 0.20 0.21 -0.44 0.22
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -8,528.40% 944.44% -10,737.04% -8,512.35% 0.00% 0.00% 0.00% -6,510.00% -7,317.78% -6,911.11%
Debt-free Net Working Capital to Revenue		 0.00% 86,134.57% 104,718.52% 95,481.48% 88,598.77% 0.00% 0.00% 0.00% 52,813.33% 46,013.33% 39,902.22%
Net Working Capital to Revenue		 0.00% 86,134.57% 95,443.21% 95,481.48% 88,598.77% 0.00% 0.00% 0.00% 52,813.33% 46,013.33% 39,902.22%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.49) ($0.33) ($0.31) ($0.38) ($0.37) ($0.21) ($0.51) ($0.22) ($0.16) ($0.20) ($0.18)
Adjusted Weighted Average Basic Shares Outstanding		 27.06M 26.60M 27.89M 30.10M 31.07M 30.07M 31.20M 31.20M 31.20M 31.20M 31.24M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($0.37) $0.00 ($0.51) ($0.22) ($0.16) ($0.20) ($0.18)
Adjusted Weighted Average Diluted Shares Outstanding		 27.41M 26.60M 29.78M 31.15M 31.07M 30.07M 31.20M 31.20M 31.20M 31.20M 31.24M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 27.41M 29.40M 29.78M 31.15M 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -10 -7.24 -6.72 -8.69 -8.82 -5.25 -12 -5.25 -3.98 -4.49 -4.13
Normalized NOPAT Margin		 0.00% -8,938.40% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4,427.11% 0.00% 0.00%
Pre Tax Income Margin		 0.00% -11,511.11% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -5,701.11% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Actinium Pharmaceuticals (NYSE: ATNM) continues to look like a development-stage biotech with limited revenue, significant operating losses, and a large cash balance that is steadily declining as the company funds R&D.

For the first quarter of 2026, the company reported no revenue and a net loss of $5.5 million, slightly better than the $5.9 million loss in Q4 2025 and the $5.1 million loss in Q3 2025. Operating expenses remained the main driver of losses, with $5.9 million in total operating expenses in Q1 2026, including $4.2 million in R&D and $1.7 million in SG&A.

Cash burn remains the biggest issue. Operating cash flow was negative $5.9 million in Q1 2026, and the company ended the quarter with $42.1 million in cash and equivalents, down from $53.4 million at the end of Q3 2025 and $65.3 million at the end of Q1 2025. While that still provides a meaningful runway, the trend shows the balance sheet is being used to fund ongoing losses.

One notable offset is the company’s deferred revenue and liabilities structure. Total liabilities were $43.1 million, including $35.0 million of noncurrent deferred revenue, which suggests some non-dilutive funding support or advance payments tied to future obligations. However, common equity was only $2.3 million in Q1 2026, reflecting the accumulation of losses over time.

  • Cash and equivalents of $42.1 million still give ATNM a substantial liquidity buffer for a clinical-stage biotech.
  • Q1 2026 net loss of $5.5 million was modestly narrower than the prior quarter’s $5.9 million loss.
  • Operating expenses declined sequentially to $5.9 million from $6.4 million in Q4 2025.
  • R&D spending fell to $4.2 million in Q1 2026 from $4.3 million in Q4 2025 and $4.2 million in Q3 2025, showing some spending discipline.
  • Interest and investment income of $381,000 helped offset a portion of operating losses.
  • The company reported no revenue in Q1 2026, which is typical for a pre-commercial biotech but means there is no sales cushion for expenses.
  • Noncurrent deferred revenue of $35.0 million remains a large liability and may create future obligations even if it supports near-term cash generation.
  • Common stock equity remains large on paper at $417.6 million, but retained earnings are deeply negative at $415.2 million, reflecting years of accumulated losses.
  • Operating cash flow was negative $5.9 million in Q1 2026, indicating the business is still consuming cash at a meaningful rate.
  • Cash declined sharply from $65.3 million in Q1 2025 to $42.1 million in Q1 2026, signaling a shrinking runway if losses persist.

Looking at the broader trend over the past year, ATNM’s quarterly losses have generally improved from the worst levels seen in early 2025 and late 2024, when net losses exceeded $15.9 million in Q1 2025 and operating cash outflows were $7.6 million. Still, the company has not yet shown a durable path to profitability or positive operating cash flow.

Bottom line: ATNM has enough cash to keep advancing its pipeline for now, but investors should expect continued losses and cash burn until the company can generate meaningful revenue or achieve a major clinical or partnering milestone.

07/20/26 03:01 PM ETAI Generated. May Contain Errors.

Actinium Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Actinium Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Actinium Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$33.89 million in 2025, rising from -$21.03 million in 2015. The previous period was -$38.24 million in 2024. Find out what analysts predict for Actinium Pharmaceuticals in the coming months.

Actinium Pharmaceuticals' total operating income in 2025 was -$36.25 million, based on the following breakdown:
  • Total Gross Profit: $90 thousand
  • Total Operating Expenses: $36.34 million

Over the last 10 years, Actinium Pharmaceuticals' total revenue changed from $0.00 in 2015 to $90 thousand in 2025, a change of 9,000,000.0%.

Actinium Pharmaceuticals' total liabilities were at $43.94 million at the end of 2025, a 0.5% decrease from 2024, and a 852.4% increase since 2015.

In the past 10 years, Actinium Pharmaceuticals' cash and equivalents has ranged from $9.25 million in 2019 to $108.91 million in 2022, and is currently $48.00 million as of their latest financial filing in 2025.

Over the last 10 years, Actinium Pharmaceuticals' book value per share changed from 0.52 in 2015 to 0.25 in 2025, a change of -52.0%.


Related Companies

Financial statements for NYSE:ATNM last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
SMX: From Under-the-Radar to Must-Watch!
SMX (Security Matters) PLC is building Digital Material Passport technology that embeds molecular-level marker...
Smallcaps Daily | Sponsoredtc pixel
Buy this stock tomorrow
Marc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership...
Chaikin Analytics | Sponsoredtc pixel
Do this before December or regret it
Porter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...
Porter & Company | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
American’s Biggest Threat Is Here
This feels like one of those ''where were you when Kennedy was shot'' moments. It felt like a moment in time, ...
Goldco Direct, LLC | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
27 insiders just called an emergency meeting
A staggering $122 million traded on Polymarket and another $64 million on Kalshi on whether America would win ...
Crypto 101 Media | Sponsoredtc pixel